<?xml version='1.0' encoding='utf-8'?>
<document id="18308561"><sentence text="Safety of repeated administrations of ixabepilone given as a 3-hour infusion every other week in combination with irinotecan in patients with advanced malignancies."><entity charOffset="38-49" id="DDI-PubMed.18308561.s1.e0" text="ixabepilone" /><entity charOffset="114-124" id="DDI-PubMed.18308561.s1.e1" text="irinotecan" /><pair ddi="false" e1="DDI-PubMed.18308561.s1.e0" e2="DDI-PubMed.18308561.s1.e0" /><pair ddi="false" e1="DDI-PubMed.18308561.s1.e0" e2="DDI-PubMed.18308561.s1.e1" /></sentence><sentence text="Epothilones are active tubulin-interacting agents that warrant combinations in clinical studies"><entity charOffset="0-11" id="DDI-PubMed.18308561.s2.e0" text="Epothilones" /></sentence><sentence text=" This phase I combination study explored ixabepilone administered as a 3-h infusion followed by a 90-minute infusion irinotecan, on days 1 and 14 of every 28-day cycle"><entity charOffset="41-52" id="DDI-PubMed.18308561.s3.e0" text="ixabepilone" /><entity charOffset="117-127" id="DDI-PubMed.18308561.s3.e1" text="irinotecan" /><pair ddi="false" e1="DDI-PubMed.18308561.s3.e0" e2="DDI-PubMed.18308561.s3.e0" /><pair ddi="false" e1="DDI-PubMed.18308561.s3.e0" e2="DDI-PubMed.18308561.s3.e1" /></sentence><sentence text=" Forty-one patients received doses of ixabepilone and irinotecan ranging from 15-30 mg/m(2) and 120-180 mg/m(2) every 2 weeks for a total of 173 cycles, respectively"><entity charOffset="38-49" id="DDI-PubMed.18308561.s4.e0" text="ixabepilone" /><entity charOffset="54-64" id="DDI-PubMed.18308561.s4.e1" text="irinotecan" /><pair ddi="false" e1="DDI-PubMed.18308561.s4.e0" e2="DDI-PubMed.18308561.s4.e0" /><pair ddi="false" e1="DDI-PubMed.18308561.s4.e0" e2="DDI-PubMed.18308561.s4.e1" /></sentence><sentence text=" Dose limiting toxicities reported at doses 25 mg/m(2) ixabepilone and 180 mg/m(2) irinotecan consisted of acute grade 3 diarrhoea and asthenia, eventually associated with neutropenia and sepsis, and/or delayed grade 3 peripheral neuropathy"><entity charOffset="55-66" id="DDI-PubMed.18308561.s5.e0" text="ixabepilone" /><entity charOffset="83-93" id="DDI-PubMed.18308561.s5.e1" text="irinotecan" /><pair ddi="false" e1="DDI-PubMed.18308561.s5.e0" e2="DDI-PubMed.18308561.s5.e0" /><pair ddi="false" e1="DDI-PubMed.18308561.s5.e0" e2="DDI-PubMed.18308561.s5.e1" /></sentence><sentence text=" Therefore, the recommended doses were 20 mg/m(2) ixabepilone and 180 mg/m(2) irinotecan"><entity charOffset="50-61" id="DDI-PubMed.18308561.s6.e0" text="ixabepilone" /><entity charOffset="78-88" id="DDI-PubMed.18308561.s6.e1" text="irinotecan" /><pair ddi="false" e1="DDI-PubMed.18308561.s6.e0" e2="DDI-PubMed.18308561.s6.e0" /><pair ddi="false" e1="DDI-PubMed.18308561.s6.e0" e2="DDI-PubMed.18308561.s6.e1" /></sentence><sentence text=" At this dose level, acute side effects were neutropenia, anaemia, nausea-vomiting, diarrhoea, asthenia, and alopecia" /><sentence text=" Delayed neuropathy was mostly restricted to reversible grade I-II" /><sentence text=" Pharmacokinetic data suggested no drug-drug interaction" /><sentence text=" Five objective responses were observed in four patients with lung cancer and one unknown primary epidermoid carcinoma patient" /><sentence text=" In conclusion, toxicity including peripheral neuropathy was manageable at the recommended doses of 20 mg/m(2) ixabepilone combined with 180 mg/m(2) irinotecan on days 1 and 14 every 28 days"><entity charOffset="111-122" id="DDI-PubMed.18308561.s11.e0" text="ixabepilone" /><entity charOffset="149-159" id="DDI-PubMed.18308561.s11.e1" text="irinotecan" /><pair ddi="false" e1="DDI-PubMed.18308561.s11.e0" e2="DDI-PubMed.18308561.s11.e0" /><pair ddi="false" e1="DDI-PubMed.18308561.s11.e0" e2="DDI-PubMed.18308561.s11.e1" /></sentence><sentence text=" Promising antitumour activity was observed in patients with platinum-pretreated lung cancer"><entity charOffset="61-69" id="DDI-PubMed.18308561.s12.e0" text="platinum" /></sentence><sentence text="" /></document>